|
SCAND2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.10410039286546E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.67050004332248E-09 |
| Normal-vs-Stage2 |
1.222420E-04 |
| Normal-vs-Stage3 |
8.65620020107372E-10 |
| Normal-vs-Stage4 |
2.23939999988154E-07 |
| Stage1-vs-Stage2 |
4.716000E-01 |
| Stage1-vs-Stage3 |
1.372630E-01 |
| Stage1-vs-Stage4 |
1.503760E-01 |
| Stage2-vs-Stage3 |
1.108810E-01 |
| Stage2-vs-Stage4 |
1.006410E-01 |
| Stage3-vs-Stage4 |
6.220400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.62100008363575E-10 |
| Normal-vs-AfricanAmerican |
9.425600E-02 |
| Normal-vs-Asian |
1.14540000040186E-07 |
| Caucasian-vs-AfricanAmerican |
1.503390E-01 |
| Caucasian-vs-Asian |
7.650000E-01 |
| AfricanAmerican-vs-Asian |
2.057600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.40849999996639E-06 |
| Normal-vs-Female |
8.64259774857601E-11 |
| Male-vs-Female |
2.279000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.88999968190274E-10 |
| Normal-vs-Age(41-60Yrs) |
4.94190000033257E-08 |
| Normal-vs-Age(61-80Yrs) |
1.21769999972265E-07 |
| Normal-vs-Age(81-100Yrs) |
2.604400E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.992800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.441000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.248000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.474200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.138800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.861600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.83026943495679E-12 |
| Classical-VS-Follicular |
2.783800E-01 |
| Classical-VS-Other |
5.200400E-01 |
| Classical-VS-Normal |
3.89679999379666E-09 |
| Tall-VS-Follicular |
1.27720000131504E-08 |
| Tall-VS-Other |
9.114300E-02 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
3.993800E-01 |
| Follicular-VS-Normal |
2.199600E-04 |
| Other-VS-Normal |
3.119800E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.52439999967902E-07 |
| Normal-vs-N1 |
5.33170000371896E-08 |
| N0-vs-N1 |
7.886000E-02 |
|
|
